Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Conbercept on plasma metabolism in diabetic macular edema
ChiCTR2400093818Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in diabetic macular edema (DME) (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Absorption of subretinal fluid, Visual acuity after treatment and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
conbercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2400093818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093818.